Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2008

01-10-2008 | Preclinical Study

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas

Authors: Gaynor J. Bates, Stephen B. Fox, Cheng Han, Rosalind Launchbury, Russell D. Leek, Adrian L. Harris, Alison H. Banham

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

We previously identified a correlation between estrogen receptor alpha (ERα) and the candidate tumour suppressor gene Forkhead Box P1 (FOXP1), whose nuclear protein expression in breast tumours was associated with improved patient survival. However, the expression pattern of FOXP1 in normal breast tissue is more reminiscent of the second receptor, ERβ, which has an emerging role as a tumour suppressor in breast cancer and critically may underlie the ability of some ERα-negative tumours to respond to tamoxifen. In a series of 283 breast cancers, in which ERα-positive tumours were treated with tamoxifen, the nuclear expression of ERβ correlated significantly with ERα (p = 0.004), low-tumour grade (p = 0.008) and nuclear FOXP1 (p = 0.01). High-grade tumours exhibited significantly more cytoplasmic ERβ than the low-grade tumours (p = 0.006). Regression analysis demonstrated that FOXP1 expression was most closely related to nuclear ERβ (p = 0.021). Neither, nuclear or cytoplasmic ERβ expression demonstrated prognostic significance. FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERα, ERβ or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism.
Literature
1.
go back to reference Wang B, Weidenfeld J, Lu MM et al (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131(18):4477–4487PubMedCrossRef Wang B, Weidenfeld J, Lu MM et al (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131(18):4477–4487PubMedCrossRef
2.
go back to reference Banham AH, Beasley N, Campo E et al (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61(24):8820–8829PubMed Banham AH, Beasley N, Campo E et al (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61(24):8820–8829PubMed
3.
go back to reference Fox SB, Brown P, Han C et al (2004) Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10(10):3521–3527PubMedCrossRef Fox SB, Brown P, Han C et al (2004) Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10(10):3521–3527PubMedCrossRef
4.
go back to reference Bieche I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosomes Cancer 14(4):227–251PubMedCrossRef Bieche I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosomes Cancer 14(4):227–251PubMedCrossRef
5.
go back to reference Martinez A, Walker RA, Shaw JA et al (2001) Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54(5):300–306PubMedCrossRef Martinez A, Walker RA, Shaw JA et al (2001) Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54(5):300–306PubMedCrossRef
6.
go back to reference Giatromanolaki A, Koukourakis MI, Sivridis E et al (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19(1):9–16PubMedCrossRef Giatromanolaki A, Koukourakis MI, Sivridis E et al (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19(1):9–16PubMedCrossRef
7.
go back to reference Banham AH, Boddy J, Launchbury R et al (2007) Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate 67(10):1091–1098PubMedCrossRef Banham AH, Boddy J, Launchbury R et al (2007) Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate 67(10):1091–1098PubMedCrossRef
8.
go back to reference Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112PubMedCrossRef Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112PubMedCrossRef
9.
go back to reference Murphy LC, Watson PH (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13(2):327–334PubMedCrossRef Murphy LC, Watson PH (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13(2):327–334PubMedCrossRef
10.
go back to reference Speirs V, Walker RA (2007) New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 211(5):499–506PubMedCrossRef Speirs V, Walker RA (2007) New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 211(5):499–506PubMedCrossRef
11.
go back to reference Gruvberger-Saal SK, Bendahl PO, Saal LH et al (2007) Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13(7):1987–1994PubMedCrossRef Gruvberger-Saal SK, Bendahl PO, Saal LH et al (2007) Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13(7):1987–1994PubMedCrossRef
12.
go back to reference McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36(2):638–644PubMedCrossRef McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36(2):638–644PubMedCrossRef
13.
go back to reference (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351(9114):1451–1467 (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351(9114):1451–1467
14.
go back to reference Speirs V, Skliris GP, Burdall SE et al (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55(5):371–374PubMed Speirs V, Skliris GP, Burdall SE et al (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55(5):371–374PubMed
15.
go back to reference Elston C (1987) Grading of invasive carcinoma of the breast. In: Page D, Anderson T (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 300–311 Elston C (1987) Grading of invasive carcinoma of the breast. In: Page D, Anderson T (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 300–311
16.
go back to reference Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20(3):358–417PubMedCrossRef Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20(3):358–417PubMedCrossRef
17.
go back to reference Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27):24353–24360PubMedCrossRef Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27):24353–24360PubMedCrossRef
18.
go back to reference Pajer P, Pecenka V, Kralova J et al (2006) Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 66(1):78–86PubMedCrossRef Pajer P, Pecenka V, Kralova J et al (2006) Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 66(1):78–86PubMedCrossRef
19.
go back to reference Speirs V, Carder PJ, Lane S et al (2004) Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5(3):174–181PubMedCrossRef Speirs V, Carder PJ, Lane S et al (2004) Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5(3):174–181PubMedCrossRef
20.
go back to reference Speirs V, Parker M, Green A et al (2006) Progress towards unlocking the secrets of oestrogen receptor beta in breast cancer. Breast Cancer Res 8(Suppl 2):P24CrossRef Speirs V, Parker M, Green A et al (2006) Progress towards unlocking the secrets of oestrogen receptor beta in breast cancer. Breast Cancer Res 8(Suppl 2):P24CrossRef
21.
go back to reference Heldring N, Pike A, Andersson S et al (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87(3):905–931PubMedCrossRef Heldring N, Pike A, Andersson S et al (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87(3):905–931PubMedCrossRef
22.
go back to reference Skliris GP, Munot K, Bell SM et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213–220PubMedCrossRef Skliris GP, Munot K, Bell SM et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213–220PubMedCrossRef
23.
go back to reference Zhao C, Lam EW, Sunters A et al (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48):7600–7606PubMedCrossRef Zhao C, Lam EW, Sunters A et al (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48):7600–7606PubMedCrossRef
24.
go back to reference Kim SJ, Kim TW, Lee SY et al (2004) CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med 14(2):289–293PubMed Kim SJ, Kim TW, Lee SY et al (2004) CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med 14(2):289–293PubMed
25.
go back to reference Rody A, Holtrich U, Solbach C et al (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12(4):903–916PubMedCrossRef Rody A, Holtrich U, Solbach C et al (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12(4):903–916PubMedCrossRef
Metadata
Title
Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas
Authors
Gaynor J. Bates
Stephen B. Fox
Cheng Han
Rosalind Launchbury
Russell D. Leek
Adrian L. Harris
Alison H. Banham
Publication date
01-10-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9812-4

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine